


Express Mail No.: EV504788940US

Atty. Dkt. No. 15060-42

REMARKS

Please enter the foregoing preliminary amendment prior to examination of the present application. Applicant respectfully submits that this Amendment presents no new matter. Early passage to issue is requested.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Gordon F. Sieckmann", is written over a horizontal line.

Gordon F. Sieckmann, Reg. No. 28,667
ARMSTRONG TEASDALE LLP
One Metropolitan Square, Ste. 2600
St. Louis, MO 63102-2740
314-621-5070

IN THE DRAWINGS

Applicants respectfully request approval of the following drawing changes.

Figures 2, 10, 13, 21, 23, 26, 28, 31 and 33 are being amended to remove excessive text. Applicants hereby submit an "Annotated Copy" of Figures 2, 10, 13, 21, 23, 26, 28, 31 and 33 showing the requested changes in red permanent ink, and a "Replacement Sheet" incorporating the changes to Figures 2, 10, 13, 21, 23, 26, 28, 31 and 33.

No new matter has been added.



Title: CALCIUM INDEPENDENT PHOSPHOLIPASE A₂ γ
POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS
THEREFOR


Inventor: Richard W. Gross et al.
Docket No.: 15060-42
Gordon F. Sieckmann, Phone 314-621-5070

5/61

ANNOTATED MARKED UP

FIGURE 2

~~iPLA₂ γ Splice Variants~~



open boxes are noncoding regions
shaded regions are putative coding regions
stippled lines represent intron splicing

FIGURE 10

Potential Alternative Exon 5 Splice Variant of Human iPLA₂^γ

A. Reported Splice Sequence (gc/ag)

Exon 5 (SEQ ID NOS 43-44)	Intron 5	Exon 6 (SEQ ID NOS 45-46)	Source
...CAG CGA GAA AAG	gcaagt...ttgttag	ATT ATC GCA AGG GTG AGT	(Tamura et al)
Q R E K		I I A R V S	BBRC 272-320, 2000

B. Potential Splice Variant (gt/ag)

Exon 5 (SEQ ID NOS 47-48)	Intron 5	Exon 6	Source
..GAA AAG GCA AGT TGT TCA GT	gtgctt..tcgcaag	G GTG AGT	(Gross lab)
E K A S C S V		V S	JBC 275-9937, 2000

The incidence of gc/ag splice variants like the one shown in "A" is 0.56%. The variant "A" has been reported in the literature, reported in GenBank, and cloned in our lab.

The splice variant gt/ag occurs with a frequency of 98.71% among genes. However, variant "B" iPLA₂^γ sequence has not been cloned.

Title: CALCIUM INDEPENDENT PHOSPHOLIPASE A₂
POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS
THEREFOR

Inventor: Richard W. Gross et al.
Docket No.: 15060-42
Gordon F. Sieckmann, Phone 314-621-5070

ANNOTATED MARKED UP

24/61

FIGURE 13





FIGURE 21

~~Additionally, iPLA₂γ sequences were inserted by ligation of 15-23mer annealed-phosphorylated oligonucleotide pairs 5' of full length luciferase coding sequence cloned into pFASTBAC via NotI/XbaI restrictions and then luciferase activity of recombinant protein produced in the Sf9 system was subsequently measured using the Luciferase Assay System of Promega.~~



Inventor: Richard W. Gross et al.
Docket No.: 15060-42
Gordon F. Sieckmann, Phone 314-621-5070

34/61

FIGURE 23. iPLA₂ Repressor Region

~~Phosphorylated oligo pairs~~
~~for repression of iPLA₂ in the luciferase expression system:~~

SEQ ID NO: 10	atgatttcacggttagctcaatttaagccaagtcctcccaattttaagaaagtatcgtagtggctggttaaaacagaaaaacatcaaca
SEQ ID NO: 32	tcgacctgatttcacggttagctcaatt
SEQ ID NO: 36	ggactaaagtgcgaatcgagtttaaccgg
SEQ ID NO: 33	
SEQ ID NO: 37	tcgactaagccaagtcctcccaatttaa
	gattcggttcaagggtttaaatccgg
SEQ ID NO: 34	
SEQ ID NO: 38	tcgacgaaaagtatcgatagtgctgg
	gctttcatagcctatcacccgaccgg
SEQ ID NO: 35	
SEQ ID NO: 39	tcgacttaaaacagaaaaacatcaaca
	gaattttgtctttttgtagtttgcgg



Title: CALCIUM INDEPENDENT PHOSPHOLIPASE A₂ γ
POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS
THEREFOR

Inventor: Richard W. Gross et al.
Docket No.: 15060-42
Gordon F. Sieckmann, Phone 314-621-5070

ANNOTATED MARKED UP

37/61

Fig. 26 Myocardial TAG Content of Fasted WT vs iPLA₂ γ Transgenic Mice



PC = Phosphatidylcholine
EG = Ethanolamine Glycerophospholipids
PM = Plasmalogen
TG = Triacylglyceride

Title: CALCIUM INDEPENDENT PHOSPHOLIPASE A₂γ
POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS
THEREFOR

Inventor: Richard W. Gross et al.
Docket No.: 15060-42
Gordon F. Sieckmann, Phone 314-621-5070

ANNOTATED MARKED UP

39/61




FIGURE 28. Quantitative PCR analysis of RNA stability of truncated iPLA₂γ S9 Expression

ANNOTATED MARKED UP





FIGURE 31

FIGURE 33

Promoter Analysis of iPLA₂ γ Pre-exon 2



Conclusion: sequence upstream of exon 2 has promoter activity. Enhancer activity resides in the region 200-400nt upstream of exon 2 (fragment IV). This region contains a CACG VNTR like sequence as well as sequences that match consensus sites for Sp1 (8), GATA1 (9), p300 (4), and Ccrl (10). GC regions upstream (1) and downstream (7) of this positive promoter region commonly are negative regulatory elements. Truncated fragments (II and VI) each lacking a GC region have enhanced promoter activity while fragments (III and V) containing the GC regions but lacking region IV have minimal promoter activity. Presumably both GC regions are required for maximal inhibition. Region IV may have less than optimal promoter activity if positive promoter elements are immediately upstream or downstream of region IV.